Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$412.00K$412.00Kderived−52.0% vs Q4 2021 Net Income-$1.23M-$1.23MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$112,000−56.4% Operating Incomederived-$1,230,000N/M Operating Cash Flowderived-$603,000N/M Free Cash Flowderived-$620,000N/M Margins · derivedGross margin27.2%−2.7 pt vs Q4 2021
Operating margin-298.5%−213.8 pt vs Q4 2021
Net margin-299.3%−213.9 pt vs Q4 2021
ended Jul 31, 2022 · filed Oct 28, 2022 · 89 d after period end